Literature DB >> 15022183

Cardiovascular effects of methamphetamine in Parkinson's disease patients.

Nicola Pavese1, Ornella Rimoldi, Alexander Gerhard, David J Brooks, Paola Piccini.   

Abstract

Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022183     DOI: 10.1002/mds.10651

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Early onset cardiovascular disease related to methamphetamine use is most striking in individuals under 30: A retrospective chart review.

Authors:  Vinita Batra; Kevin S Murnane; Brianne Knox; Amber N Edinoff; Yahya Ghaffar; Laura Nussdorf; Murray Petersen; Sarah E Kaufman; Sania Jiwani; Christopher A Casey; Stephanie Terhoeve; Mohammad Alfrad Nobel Bhuiyan; Paari Dominic; Shawn McNeil; James Patterson
Journal:  Addict Behav Rep       Date:  2022-05-18

3.  Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

Authors:  Zaid A Abassi; Ofer Binah; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

4.  The clinical pharmacology of intranasal l-methamphetamine.

Authors:  John E Mendelson; Dana McGlothlin; Debra S Harris; Elyse Foster; Tom Everhart; Peyton Jacob; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2008-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.